Friday, 24 Jan 2020

You are here

RA Disease Activity Drives Lung Complications

A longitudinal study from the BRASS registry shows that increase rheumatoid arthritis (RA) disease activity increases the risk of RA-associated interstitial lung disease (RA-ILD).

RA patients without RA-ILD at baseline, enrolled in the Brigham RA Sequential Study (BRASS, 2003–2016), were followed from 2003-2016 with serial clinical, DAS28, serologic and imaging assessments. 

From a total of 1,419 RA (mean age 55.8 years; 2/3 seropositive) they identied 85 incident cases of RA-ILD after a mean follow- up duration of 8.9 years per patient. 

Those with moderate/high disease activity group had a two fold increase (HR of 2.22;95% CI 1.28–3.82) for RA-ILD compared to the remission/low disease activity group.

The Risk of RA-ILD according to DAS 28 disease activity:

  • Remission: HR 1.00 (reference)
  • Low disease activity: HR 1.41 (95% CI 0.61–3.28)
  • Moderate disease activity: HR 2.08 (95% CI 1.06–4.05)
  • High disease activity: HR 3.48 (95% CI 1.64–7.38) (P for trend = 0.001).

For each unit increase in the DAS28, the risk of RA-ILD increased by 35%. Results were similar in analyses adjusted for of methotrexate, glucocorticoids, bone erosions, or rheumatoid nodules.

These findings suggest the importance of reducing disease activity and systemic inammation to alter the risk or progression of RA-ILD in the future.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Low Risk of Inflammatory Arthritis in Hidradenitis Suppurativa Patients

JAMA Dermatology reports that after the onset and diagnosis of hidradenitis suppurativa (HS), such patients have a higher risk of certain forms inflammatory arthritis.

Best of 2019 - War on RA - Part 1: Walk on the Moon

It’s a great time to be a rheumatologist and to manage RA. But, if you keep doing what you’re doing, you’re going to keep getting what you’ve got.

Best of 2019 - War on RA - Part 3: Useless Drugs

We have options that are endless – we have 28 biologics in rheumatology; 19 approved for RA in the last 20 years, but 15 of these are me-too copies or biosimilars. We currently have 2 JAK inhibitors and may have 3 or 4 by year end. But what we really need is the right drug, at the right time, in the right patient – but how will we know.

Link Between Obstructive Lung Disease and Developing RA?

We all know that the microbiome in the gut may be very important for multiple immune diseases. However, new findings from the ACR, 2019 in Atlanta reinforce how important the interface is between the lungs and developing rheumatoid arthritis.

Smoking Cessation Lowers RA Disease Activity and CV Risks

A multinational cross-sectional cohort study suggests that smoking cessation in rheumatoid arthritis (RA) patients is associated with lower disease activity measures, improved lipid profiles and lower rates of cardiovascular (CV) events.